JP2022518354A5 - - Google Patents

Info

Publication number
JP2022518354A5
JP2022518354A5 JP2021535753A JP2021535753A JP2022518354A5 JP 2022518354 A5 JP2022518354 A5 JP 2022518354A5 JP 2021535753 A JP2021535753 A JP 2021535753A JP 2021535753 A JP2021535753 A JP 2021535753A JP 2022518354 A5 JP2022518354 A5 JP 2022518354A5
Authority
JP
Japan
Prior art keywords
suspension
patient
regimen
raav
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067316 external-priority patent/WO2020132155A1/en
Publication of JP2022518354A publication Critical patent/JP2022518354A/ja
Publication of JP2022518354A5 publication Critical patent/JP2022518354A5/ja
Pending legal-status Critical Current

Links

JP2021535753A 2018-12-20 2019-12-19 家族性高コレステロール血症を治療するための遺伝子療法 Pending JP2022518354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782627P 2018-12-20 2018-12-20
US62/782,627 2018-12-20
PCT/US2019/067316 WO2020132155A1 (en) 2018-12-20 2019-12-19 Gene therapy for treating familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
JP2022518354A JP2022518354A (ja) 2022-03-15
JP2022518354A5 true JP2022518354A5 (cg-RX-API-DMAC7.html) 2022-12-23

Family

ID=71101865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535753A Pending JP2022518354A (ja) 2018-12-20 2019-12-19 家族性高コレステロール血症を治療するための遺伝子療法

Country Status (9)

Country Link
US (1) US20220040332A1 (cg-RX-API-DMAC7.html)
EP (1) EP3902918A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022518354A (cg-RX-API-DMAC7.html)
KR (1) KR20210106489A (cg-RX-API-DMAC7.html)
CN (1) CN113710808A (cg-RX-API-DMAC7.html)
AU (1) AU2019401638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3123844A1 (cg-RX-API-DMAC7.html)
IL (1) IL284121A (cg-RX-API-DMAC7.html)
WO (1) WO2020132155A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887723A (zh) * 2024-01-08 2024-04-16 苏州诺洁贝生物技术有限公司 密码子优化的ldlr基因及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1224186A1 (zh) * 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US11555059B2 (en) * 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
EP4085934A1 (en) * 2015-12-11 2022-11-09 The Trustees of The University of Pennsylvania Gene therapy for treating familial hypercholesterolemia

Similar Documents

Publication Publication Date Title
US20220347297A1 (en) Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
JP2022511776A5 (cg-RX-API-DMAC7.html)
JP2022516283A5 (cg-RX-API-DMAC7.html)
JP2021523198A5 (cg-RX-API-DMAC7.html)
JP2025060641A5 (cg-RX-API-DMAC7.html)
EP3963055A1 (en) Vectorized antibodies (vab) and uses thereof
US20100035973A1 (en) Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines
JP2018535929A5 (cg-RX-API-DMAC7.html)
JP2022522776A5 (cg-RX-API-DMAC7.html)
US20190002915A1 (en) Compositions and methods for regulatable antibody expression
JP2024515459A5 (cg-RX-API-DMAC7.html)
JP2020537637A5 (cg-RX-API-DMAC7.html)
JP2019504003A5 (cg-RX-API-DMAC7.html)
JP2025506383A5 (cg-RX-API-DMAC7.html)
US20190240328A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
JP2022547541A5 (cg-RX-API-DMAC7.html)
JP2024517143A5 (cg-RX-API-DMAC7.html)
EP4165196A1 (en) Methods and compositions for expressing phenylalanine hydroxylase
McCormack et al. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease
Di Minno et al. Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
US20030130221A1 (en) Induction of tolerance to a therapeutic polypeptide
JP2025506681A5 (cg-RX-API-DMAC7.html)
WO2022006253A2 (en) Methods and compositions for administering recombinant viral vectors
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
CN119095612A (zh) 用于在长期停止gaa酶替代疗法的情况下治疗庞贝病的治疗性腺相关病毒